Related Experiment Video
Updated: Oct 18, 2025
09:13
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
1.6K
Targeting Host Glycolysis as a Strategy for Antimalarial Development.
Andrew J Jezewski1,2, Yu-Hsi Lin3, Julie A Reisz4
1Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
Frontiers in Cellular and Infection Microbiology
|October 4, 2021
Summary
New antiglycolytic therapies targeting enolase show promise but can cause anemia. This study reveals enolase inhibition in red blood cells leads to oxidative damage and premature aging, offering insights into malaria pathogenesis.
Area of Science:
- Biochemistry
- Cell Biology
- Pathology
Background:
- Glycolysis is crucial for cellular energy, redox balance, and biosynthesis.
- Antiglycolytic therapies are explored for obesity, cancer, aging, autoimmunity, and microbial diseases.
- Anemia is a dose-limiting side effect of current antiglycolytic inhibitors.
Purpose of the Study:
- To develop specific inhibitors of enolase, a key glycolytic enzyme.
- To investigate the metabolic and cellular effects of enolase inhibition on human erythrocytes.
- To apply findings to understand red blood cell toxicity and malaria pathogenesis.
Main Methods:
- Development of specific enolase inhibitors.
- Validation of metabolic and cellular effects on human erythrocytes.
- Application of a red blood cell toxicity model to malaria.
Main Results:
- Enolase inhibition increases erythrocyte susceptibility to oxidative damage.
- Enolase inhibition induces premature erythrocyte senescence, not direct hemolysis.
- Erythrocyte glycolytic disruption impacts malaria parasite growth.
Conclusions:
- Enolase inhibition in erythrocytes causes oxidative damage and premature aging.
- This provides a model for understanding red blood cell homeostasis and toxicity.
- Erythrocyte reductive capacity is vital for malaria parasite survival.
